Artelo Biosciences Inc ARTL

Healthcare

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. It is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.

NDAQ:ARTL - Post by User

Artelo Biosciences Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Feb 15, 2024 10:00pm

53 Views

Post# 35883374

Artelo Biosciences to Present at the Winter Wrap-Up MicroCap

Just In: $ARTL Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thSOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it w...ARTL - Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario